Diagnostic value of urinary luteinizing hormone levels in the monitoring of precocious puberty treatment

Creative Commons License

Yuce O., Bideci A., Çelik N., Camurdan O., Cinaz P.

ARCHIVES OF ENDOCRINOLOGY METABOLISM, vol.64, no.2, pp.121-127, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 64 Issue: 2
  • Publication Date: 2020
  • Doi Number: 10.20945/2359-3997000000212
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Page Numbers: pp.121-127
  • Keywords: Monitoring, precocious puberty, urinary gonadotropin, GnRH analogues, GONADOTROPIN MEASUREMENTS, DEPOT LEUPROLIDE, LH, CHILDREN, EXCRETION, HEIGHT, SERUM, GIRLS, AXIS, AGE
  • Gazi University Affiliated: Yes


Objective: To determine whether first-voided urinary LH (FV-ULH) - level measurement can adequately assess pubertal suppression as much as standard tests can. Subjects and methods: The study group included patients with central precocious puberty and rapidly progressing early puberty who received up to 3 - 4 doses of GnRHa therapy monthly and did not have adequate hormonal suppression after GnRH stimulation (90-minute LH level > 4 IU/L). Design: All of the participants underwent an LHRH test just after admission to the study. According to the stimulated peak LH levels, the patients were divided into 2 groups and followed until the end of the first year of treatment.The concordance between FV-ULH and stimulated LH levels was assessed. Results: The FV-ULH levels in patients with inadequate hormonal suppression were significantly high compared to patients with adequate hormonal suppression. FV-ULH levels were very strongly correlated with stimulated LH levels (r = 0.91). Its correlation with basal LH levels was significant (r = 0.65). However, this positive correlation was modestly weakened after the first year of treatment.The cutoff value for FV-ULH of 1.01 mlU/mL had the highest sensitivity (92.3%) and specificity (100%). Conclusion: FV-ULH levels, using more reliable and sensitive assay methods, can be used to monitor the adequacy of GnRHa therapy.